1.A multi-omics-empowered framework for precision diagnosis and treatment of lysosomal diseases.
Nguyen Thi Hai YEN ; Nguyen Tran Nam TIEN ; Nguyen Quang THU ; Franklin DUCATEZ ; Wladimir MAUHIN ; Olivier LIDOVE ; Soumeya BEKRI ; Abdellah TEBANI ; Nguyen Phuoc LONG
Journal of Pharmaceutical Analysis 2025;15(10):101274-101274
Lysosomal diseases (LDs) are a group of rare inherited disorders belonging to inborn metabolism errors. LDs are characterized by the excessive storage of undegraded substrates, most often due to the enzymatic deficiency resulting from disease-causing gene variants. LDs lead to dysregulated cellular pathways and imbalanced molecular homeostasis and can affect multiple organs and tissues. Despite being rare, LDs account for a significant incidence when considered collectively. Due to complex molecular and genetic fingerprints, considerable challenges in LD management must be overcome. Diagnosis can be significantly delayed due to the broad and nonspecific clinical manifestations and the lack of specific biomarkers. Available treatments fail to fully stop the disease progression and can alter the disease's typical phenotypes with novel manifestations. Therefore, a paradigm shift is crucial to better understand LDs and provide actionable insights. Herein, we comprehensively review the literature to demonstrate that multi-omics approaches are promising for pathophysiology elucidation, biomarker discovery, and precision therapy in LDs. We recommend adopting longitudinal study designs integrated with a multi-omics-empowered framework to facilitate mechanistic delineation, biomarker discovery, and treatment development. Relevant approaches exploring the association between LDs and common neurodegenerative disorders are also discussed, paving a potential path for improved therapeutic development and ultimately improving the patient's quality of life.
2.Push forward LC-MS-based therapeutic drug monitoring and pharmacometabolomics for anti-tuberculosis precision dosing and comprehensive clinical management.
Nguyen Quang THU ; Nguyen Tran Nam TIEN ; Nguyen Thi Hai YEN ; Thuc-Huy DUONG ; Nguyen Phuoc LONG ; Huy Truong NGUYEN
Journal of Pharmaceutical Analysis 2024;14(1):16-38
The spread of tuberculosis (TB), especially multidrug-resistant TB and extensively drug-resistant TB, has strongly motivated the research and development of new anti-TB drugs. New strategies to facilitate drug combinations, including pharmacokinetics-guided dose optimization and toxicology studies of first- and second-line anti-TB drugs have also been introduced and recommended. Liquid chromatography-mass spectrometry (LC-MS) has arguably become the gold standard in the analysis of both endo- and exo-genous compounds. This technique has been applied successfully not only for therapeutic drug monitoring (TDM) but also for pharmacometabolomics analysis. TDM improves the effectiveness of treatment, reduces adverse drug reactions, and the likelihood of drug resistance development in TB patients by determining dosage regimens that produce concentrations within the therapeutic target window. Based on TDM, the dose would be optimized individually to achieve favorable outcomes. Pharmacometabolomics is essential in generating and validating hypotheses regarding the metabolism of anti-TB drugs, aiding in the discovery of potential biomarkers for TB diagnostics, treatment monitoring, and outcome evaluation. This article highlighted the current progresses in TDM of anti-TB drugs based on LC-MS bioassay in the last two decades. Besides, we discussed the advantages and disadvantages of this technique in practical use. The pressing need for non-invasive sampling approaches and stability studies of anti-TB drugs was highlighted. Lastly, we provided perspectives on the prospects of combining LC-MS-based TDM and pharmacometabolomics with other advanced strategies (pharmacometrics, drug and vaccine developments, machine learning/artificial intelligence, among others) to encapsulate in an all-inclusive approach to improve treatment outcomes of TB patients.
3.Study on the proportion of patients with uncontrolled hypertension among outpatients and related factors at the Internal Medicine Clinic, Hue university of medicine and Pharmacy Hospital
Vu Thao Vy NGUYEN ; Thi Bich Thuy LE ; Pham Phuoc Long DOAN ; Thi Thanh Nhan TRAN ; Phuoc Thuoc DOAN
Hue Journal of Medicine and Pharmacy 2023;13(7):190-197
Background: Hypertension is one of the dangerous chronic diseases. In the treatment of hypertension, controlling blood pressure to achieve treatment target is paramount to prevent dangerous complications and death. The study was conducted to identify the percentage of hypertensive patients who do not achieve treatment target among outpatients at the internal medicine clinic, Hue University of Medicine and Pharmacy Hospital, and explore some related factors. Methods: A cross-sectional study was conducted among 403 hypertensive patients treated as outpatients at the internal medicine clinic. A multivariate logistic regression model was used to identify the related factors. Results: 46.4% of hypertensive patients did not reach the treatment target. Factors related to uncontrolled hypertension were male, non-religion, comorbidities, no reduction in salt intake, the use of coffee/tea, and non-compliance with medication (p < 0.05). Conclusions: The rate of patients with uncontrolled hypertension was still high. The health sector should consider establishing an outpatient management team; strengthening communication activities and advice on diet and drug use in parallel with medical examination and treatment.
4.Caenorhabditis elegans deep lipidome profiling by using integrative mass spectrometry acquisitions reveals significantly altered lipid networks
Anh Hoang NGUYEN ; Yoon Cheol YOUNG ; Min Jin YOUNG ; Long Phuoc NGUYEN ; Jung Woon CHEOL ; Kim Jo SUN ; Kim Won SUK ; Lee Goo EUN ; Wang DAIJIE ; Wang XIAO ; Kwon Won SUNG
Journal of Pharmaceutical Analysis 2022;12(5):743-754
Lipidomics coverage improvement is essential for functional lipid and pathway construction.A powerful approach to discovering organism lipidome is to combine various data acquisitions,such as full scan mass spectrometry(full MS),data-dependent acquisition(DDA),and data-independent acquisition(DIA).Caenorhabditis elegans(C.elegans)is a useful model for discovering toxic-induced metabolism,high-throughput drug screening,and a variety of human disease pathways.To determine the lipidome of C.elegans and investigate lipid disruption from the molecular level to the system biology level,we used integrative data acquisition.The methyl-tert-butyl ether method was used to extract L4 stage C.elegans after exposure to triclosan(TCS),perfluorooctanoic acid,and nanopolystyrene(nPS).Full MS,DDA,and DIA integrations were performed to comprehensively profile the C.elegans lipidome by Q-Exactive Plus MS.All annotated lipids were then analyzed using lipid ontology and pathway analysis.We annotated up to 940 lipids from 20 lipid classes involved in various functions and pathways.The biological in-vestigations revealed that when C.elegans were exposed to nPS,lipid droplets were disrupted,whereas plasma membrane-functionalized lipids were likely to be changed in the TCS treatment group.The nPS treatment caused a significant disruption in lipid storage.Triacylglycerol,glycerophospholipid,and ether class lipids were those primarily hindered by toxicants.Finally,toxicant exposure frequently involved numerous lipid-related pathways,including the phosphoinositide 3-kinase/protein kinase B pathway.In conclusion,an integrative data acquisition strategy was used to characterize the C elegans lipidome,providing valuable biological insights into hypothesis generation and validation.

Result Analysis
Print
Save
E-mail